ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 247 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,964,302 | +89.4% | 142,241 | +117.6% | 0.11% | +86.4% |
| Q2 2023 | $1,565,396 | +8.6% | 65,361 | -14.7% | 0.06% | -1.7% |
| Q1 2023 | $1,441,800 | +374.7% | 76,610 | +301.5% | 0.06% | +233.3% |
| Q4 2022 | $303,754 | -47.4% | 19,080 | -45.9% | 0.02% | -50.0% |
| Q3 2022 | $577,000 | +25.2% | 35,255 | +7.9% | 0.04% | +111.8% |
| Q2 2022 | $461,000 | -18.8% | 32,687 | +34.4% | 0.02% | -34.6% |
| Q4 2021 | $568,000 | +111.2% | 24,319 | +120.5% | 0.03% | +52.9% |
| Q2 2021 | $269,000 | -74.5% | 11,030 | -73.0% | 0.02% | -67.3% |
| Q1 2021 | $1,055,000 | +133.4% | 40,875 | +383.7% | 0.05% | +160.0% |
| Q4 2020 | $452,000 | -78.2% | 8,450 | -83.2% | 0.02% | -79.4% |
| Q3 2020 | $2,072,000 | +158.4% | 50,240 | +203.5% | 0.10% | +136.6% |
| Q2 2020 | $802,000 | +3.4% | 16,552 | -8.8% | 0.04% | +20.6% |
| Q4 2019 | $776,000 | +28.7% | 18,151 | -19.5% | 0.03% | +3.0% |
| Q2 2019 | $603,000 | – | 22,550 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |